Ownership and insider activity for Lisata Therapeutics, Inc. (LSTA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues.
Price
| Price | $1.74 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-01-09 | Mazzo David J | A-Award | 81,000 | |
| 2026-01-09 | Mazzo David J | F-InKind | 10,503 | $21K |
| 2026-01-09 | Mazzo David J | F-InKind | 10,515 | $21K |
| 2026-01-09 | Mazzo David J | F-InKind | 12,224 | $24K |
| 2026-01-09 | Mazzo David J | F-InKind | 7,854 | $15K |
| 2026-01-09 | Mazzo David J | A-Award | 40,000 | $79K |
| 2026-01-09 | Nisco James | A-Award | 15,000 | |
| 2026-01-09 | Nisco James | F-InKind | 2,131 | $4K |
| 2026-01-09 | Nisco James | F-InKind | 2,131 | $4K |
| 2026-01-09 | Nisco James | F-InKind | 1,137 | $2K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.7M | $29.2M | $10.3M | $14.0M | $16.5M | $24.6M | $32.2M | $22.6M | $16.2M | $16.0M |
| Short-term Investments | 0 | $25.9M | $32.8M | $11.1M | $18.1M | $70.3M | $37.1M | $27.9M | $15.0M | 0 |
| Receivables | $138774 | $234461 | 0 | 0 | 0 | 0 | 0 | 0 | $900000 | $700000 |
| Inventory | $3.6M | $5.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $24.6M | $61.1M | $44.1M | $26.0M | $35.3M | $96.2M | $71.9M | $53.9M | $34.6M | $17.7M |
| Property, Plant & Equipment | $17.1M | $256900 | $165000 | $100000 | $57000 | $62000 | $296000 | $175000 | $72000 | $18000 |
| Goodwill | $7.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $2.3M | 0 | 0 | 0 | 0 | 0 | $334000 | $263000 | $192000 | 0 |
| Total Assets | $51.8M | $63.4M | $44.6M | $27.2M | $36.0M | $97.0M | $73.0M | $54.7M | $35.0M | $17.7M |
| Accounts Payable | $2.2M | $1.3M | $762000 | $1.5M | $1.0M | $1.9M | $2.7M | $2.4M | $1.3M | $1.0M |
| Short-term Debt | $3.7M | $159000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $19.5M | $9.3M | $5.6M | $6.0M | $3.5M | $4.5M | $6.4M | $6.6M | $5.6M | $3.1M |
| Long-term Debt | $2.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $47.8M | $13.2M | $7.1M | $6.6M | $3.8M | $5.0M | $6.7M | $6.8M | $5.7M | $3.1M |
| Retained Earnings | -$404.8M | -$381.8M | -$398.0M | -$417.4M | -$425.6M | -$453.0M | -$507.2M | -$528.1M | -$548.1M | -$564.7M |
| Total Equity | $4.9M | $50.5M | $37.7M | $20.8M | $32.5M | $92.3M | $66.6M | $48.1M | $29.6M | $14.9M |
| Total Debt | $6.8M | $159180 | 0 | $978000 | $624000 | $714000 | $485000 | $168000 | $137000 | 0 |
| Net Debt | -$7.9M | -$54.9M | -$43.1M | -$24.2M | -$33.9M | -$94.3M | -$68.7M | -$50.4M | -$31.1M | -$16.0M |
| Working Capital | $5.1M | $51.8M | $38.5M | $20.0M | $31.8M | $91.7M | $65.5M | $47.3M | $29.0M | $14.6M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.76 |
Profitability
| Return on Equity | -111.65% |
| Return on Invested Capital | -117.30% |
| Return on Assets | -93.47% |
| Gross Margin | 14.12% |
| Operating Margin | -10711.18% |
| Net Margin | -9756.47% |
Related companies: CASI · CLGN · CLSD · ENLV · KLTO · MTVA · NCNA
Explore sector: Healthcare · Biotechnology
More sections of LSTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks